Healthy Subjects Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3652 in Healthy Young and Elderly Male and Female Subjects
The study investigates how safe ASP3652 is and how well it is tolerated when taken as
multiple doses. The study also assesses how quickly and to what extent it is absorbed and
eliminated from the body. In addition, the effects of age and gender are investigated.
The study consists of two parts. In Part 1 four dose levels are administered to four
separate groups initially. Two additional dosages are then investigated. Subjects receive
either a once-daily dose (QD) or twice-daily dose (BID) of ASP3652 or placebo.
Part 2 is performed in one group of elderly healthy male or female (post-menopausal)
subjects. Subjects receive either a twice daily dose (BID) of ASP3652 or placebo.
For both parts of the study, the subjects stay in the clinic for one period of 18 days.
This is a Multiple Ascending Dose (MAD) study with two parts. Screening for both parts takes
place between Days -28 and -3. Subjects are admitted to the clinic on Day -2, and discharged
on Day 16. They return for an End of Study Visit (ESV) between 7 and 14 days after (early)
discharge.
Part 1 evaluates the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)
of ASP3652 following ascending multiple oral doses. The initially planned four dose levels
or matching placebo are given to four separate groups. Thereafter two additional dosage
levels are further investigated. All groups receive a single dose of ASP3652 administered in
the morning of Day 1 and Day 14, and twice-daily doses administered from Day 2 to Day 13
under fasted conditions, except the last group which receives all dosages once daily from
Day 1 to Day 14.
Part 2 evaluates the safety, tolerability, PK and PD of ASP3652 following ascending multiple
oral doses in healthy elderly male and female subjects. This part contains a single,
placebo-controlled group. All subjects receive twice daily doses and administration is based
on the results of Part 1.
All subjects in both parts receive training for Neurocognitive Test Battery (NTB) and tests
for monitoring of psychotropic effects.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
| Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
| Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
| Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
| Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
| Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
| Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
| Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
| Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
| Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
| Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
| Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
| Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
| Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
| Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |